Effects of Foot Bath Therapy on Peripheral Neuropathy, Sleep Disorder, and Fatigue in Gynecologic Patients with Cancer Undergoing Chemotherapy

ObjectiveTo explore the association of peripheral neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) use in patients with cancer.MethodsPublished data search up to November 2018 reporting peripheral neuropathy in patients with cancer treated with VEGFR-TKIs was performed. The primary outcome was presence of peripheral neuropathy at the end of the trial. Random-effects meta-analysis was performed to estimate relative risk (RR) of individual treatment.ResultsThirty randomized clinical trials (RCTs) including 12,490 patients with cancer were included in this analysis. Eight studies compared VEGFR-TKIs with placebo and the remaining studies compared VEGFR-TKIs with the standard chemotherapeutic regimen. When compared against placebo, VEGFR-TKIs were associated with a higher risk of peripheral neuropathy (RR 1.76; 95% confidence interval [CI] 1.13–2.75, p = 0.01). Similarly, a stronger association was noted for sensory neuropathy with VEGFR-TKIs monotherapy (RR 1.61; 95% CI 1.09–2.37, p = 0.02). Risk of peripheral neuropathy with VEGFR-TKIs was higher even when they were compared against control (either placebo or standard chemotherapeutic agents) (RR 1.08; 95% CI 1.01–1.15, p = 0.03). High-grade neuropathy (RR 1.28; 95% CI 1.06–1.54, p <0.01) and high-grade sensory neuropathy (RR 1.38; 95% CI 1.09–1.74, p < 0.01) were noted more frequently with VEGFR-TKIs treatment compared against control.ConclusionsVEGFR-TKIs therapy appeared to be associated with an increased risk of neuropathy.

Download Full-text

Effect of duloxetine on chemotherapy-induced painful peripheral neuropathy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.31_suppl.181 ◽

2014 ◽

Vol 32 (31_suppl) ◽

pp. 181-181 ◽

Cited By ~ 1

Author(s):

Yasuo Hirayama ◽

Takeshi Terui ◽

Kazuhiko Koike ◽

Toshiro Kusakabe ◽

Hiroto Horiguthi ◽

...

Keyword(s):

Peripheral Neuropathy ◽

Adverse Effects ◽

Medical Information ◽

Japanese Patients ◽

Drop Out ◽

University Hospital ◽

Open Label ◽

Patients With Cancer ◽

Vas Scores ◽

Primary Hypothesis

181 Background: Approximately 20% to 40% of patients with cancer who receive neurotoxic chemotherapy will develop painful chemotherapy-induced peripheral neuropathy. Smith et. al firstly reported that duloxetine was effective on above neuropathy after taxanes and platinums (JAMA 2013), so we planed to evaluate the duloxetine effect in Japanese patients after above drugs and more expanding drugs include vinca alkaloids and bortezomib. Methods: Patients were randomized to receive either duloxetine followed by vitamin(V)B12 or VB12 by duloxetine. The initial treatment consisted of 20 mg of duloxetine or 1.5g VB12 for the first week and 40mg of duloxetine or VB12 daily for 3 additional weeks (an open label, randomized, crossover). Dose reduction by the adverse effects was permitted. The primary hypothesis was that duloxetine would be more effective than VB12 in decreasing chemotherapy-induced peripheral neuropathic pain. Numbness and Pain severity were assessed weekly using visual analogue scale (VAS). This research was approved by the Research Ethics Committee of Higashi Sapporo Hospital and University Hospital Medical Information Network (UMIN) Center in Japan.Thirty-four cases (Breast cancer: taxanes 2, gastric cancer: taxane 5, colon cancer: oxaliplatin 6, Malignant lymphoma: vincristine 13, multiple myeloma: bortezomib 8) were made an entry in our institution. Five cases dropped out because of the adverse effect with sleepy and general malaise. Results: Obvious improvements of VAS scores of numbness and pain were observed in duloxetine group. Significant differences of delta VAS (pre VAS scale – 4 weeks VAS after drug administration) were observed between duloxetine group and VB12 group in the aspect of numbness (p=0.02) and pain (p=0.03). Conclusions: Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with VB12 for 4 weeks resulted in a reduction in numbness and pain, but there are many cases with drop out by the adverse effects. Clinical trial information: 000011554.

Download Full-text

Measuring treatment-induced peripheral neuropathy in patients with cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e21674 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e21674-e21674

Author(s):

Tito R. Mendoza ◽

Loretta A. Williams ◽

Qiuling Shi ◽

Xin Shelley Wang ◽

Shireen Haq ◽

...

Keyword(s):

Peripheral Neuropathy ◽

Patients With Cancer

Download Full-text

An Overview of Chemotherapy-Induced Peripheral Neuropathy

Journal of Pharmacy Practice ◽

10.1177/0897190008315056 ◽

2008 ◽

Vol 21 (2) ◽

pp. 138-145 ◽

Cited By ~ 1

Author(s):

Jose R. Murillo ◽

James E. Cox ◽

Michael S. Oholendt

Keyword(s):

Adverse Event ◽

Peripheral Neuropathy ◽

Positive Impact ◽

Chemotherapeutic Agents ◽

Patient Specific ◽

Drug Discontinuation ◽

Neurologic Complication ◽

Patients With Cancer ◽

Neurological Adverse Event

Peripheral neuropathy remains a major limitation of chemotherapeutic agents used in cancer treatment. This neurologic complication from chemotherapy occurs frequently and can be debilitating. Although difficult to predict, both chemotherapeutic and patient-specific risk factors may contribute to this adverse event. Symptoms of peripheral neuropathy may appear acutely after treatment or persist chronically upon drug discontinuation. The taxanes, vinca alkaloids, and immunomodulatory drugs commonly cause peripheral nervous system toxicity. Prompt recognition and evaluation of this neurological adverse event by those who provide care to patients with cancer can prove to have a positive impact on the quality of life of those patients.

Download Full-text

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy

International Journal of Molecular Sciences ◽

10.3390/ijms22020888 ◽

2021 ◽

Vol 22 (2) ◽

pp. 888

Author(s):

Shota Yamamoto ◽

Nobuaki Egashira

Keyword(s):

Peripheral Neuropathy ◽

First Generation ◽

Hematologic Malignancy ◽

Patients With Cancer ◽

Potential Efficacy ◽

Anti Cancer ◽

Central Nervous Systems ◽

Critical Problems ◽

Approved Drugs ◽

Dose Limiting Toxicity

Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for hematologic malignancy, has effective anti-cancer activity but often causes severe peripheral neuropathy. Although bortezomib-induced peripheral neuropathy (BIPN) is a dose-limiting toxicity, there are no recommended therapeutics for its prevention or treatment. One of the most critical problems is a lack of knowledge about pathological mechanisms of BIPN. Here, we summarize the known mechanisms of BIPN based on preclinical evidence, including morphological abnormalities, involvement of non-neuronal cells, oxidative stress, and alterations of transcriptional programs in both the peripheral and central nervous systems. Moreover, we describe the necessity of advancing studies that identify the potential efficacy of approved drugs on the basis of pathological mechanisms, as this is a convincing strategy for rapid translation to patients with cancer and BIPN.

Download Full-text

The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer – a population-based cross-sectional study

Acta Oncologica ◽

10.1080/0284186x.2021.2007283 ◽

2021 ◽

pp. 1-8

Author(s):

Sebastian Werngreen Nielsen ◽

Lise Eckhoff ◽

Christina Halgaard Bruvik Ruhlmann ◽

Jørn Herrstedt ◽

Susanne Oksbjerg Dalton

Keyword(s):

Peripheral Neuropathy ◽

Population Based ◽

Cross Sectional Study ◽

Sectional Study ◽

Cross Sectional ◽

Patients With Cancer

Download Full-text

Resumption of the Treatment for Non-COVID-19 Gynecologic Patients after Lifting Lock down: Experiences from Wuhan

10.21203/rs.3.rs-63125/v1 ◽

2020 ◽

Author(s):

Weihong Dong ◽

Rui Gao ◽

Jing Cai ◽

Shouhua Yang ◽

Jianfeng Guo ◽

...

Keyword(s):

Virus Disease ◽

Screening Tests ◽

Symptom Monitoring ◽

Patients With Cancer ◽

Outpatient Visits ◽

Union Hospital ◽

Risk Patients ◽

The City ◽

Gynecologic Patients ◽

Timely Treatment

Abstract Background: To share our experiences of resumption of the treatment for gynecologic patients after lifting lockdown in a hotspot area of the Corona Virus Disease 2019 (COVID-19)pandemic.Methods: The triage process used to resume the medical activities for gynecologic patients at the Wuhan Union Hospital after a 76-day lockdown of the city is described and its effectiveness to avoid COVID-19 nosocomial transmission is shown.Results:The non-emergency patients are pre-triaged by contact history and body temperature at outpatient clinic and negative COVID-19 screening tests are required for an admissionin the buffering rooms at the gynecologic department. The buffering lastsfor at least three days for symptom monitoring and a second round of COVID-19 tests before they can be transferred to the regular gynecologic wards. For patients who need emergency surgery, the first screening should be completed at the quarantine wards after the surgery, followed by buffering at the gynecologic department. We received 19298 outpatient visits, admitted 326 patients, and performed 223 operations in the first two months after the lockdown was lifted, andno single COVID-19 case occurredin the hospitalized patients while the proportion of potentially high-risk patients with cancer and severe anemia were increased in comparison with the same period in 2019 and the latest two months before the lockdown.Conclusions:We provide an effective triage system with buffering at two levels to guarantee safe and timely treatment for non-COVID-19 gynecologic patients in a post-lockdown phase.

Download Full-text

Evaluation and Management of Peripheral Neuropathy in Diabetic Patients With Cancer

Clinical Journal of Oncology Nursing ◽

10.1188/08.cjon.243-247 ◽

2008 ◽

Vol 12 (2) ◽

pp. 243-247 ◽

Cited By ~ 18

Author(s):

Constance Visovsky ◽

Rachel R. Meyer ◽

Jeffre Roller ◽

Megan Poppas

Keyword(s):

Peripheral Neuropathy ◽

Diabetic Patients ◽

Patients With Cancer

Download Full-text